Compare Estee Lauder Companies Inc (EL) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Medpace Holdings Inc — how do they compare? Estee Lauder Companies Inc trades at $88.22 (market cap $31.76B), while Medpace Holdings Inc trades at $598 (market cap $16.90B). The key difference: Estee Lauder Companies Inc is the larger of the two by market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| EL | MEDP | |
|---|---|---|
Market Cap | $31.76B | $16.90B |
Sector | Consumer Staples | Technology |
52-Week High | $119.61 | $620.59 |
52-Week Low | $67.23 | $393.42 |
Enterprise Value | $37.93B | $16.52B |
Dividend Yield | 1.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EL trades at $87.70, up 0.58% on the day, with a bullish technical signal from moving averages and a consensus price target of $91.67. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.13 billion for 2025. Revenue has declined from $17.7 billion in 2022 to $14.33 billion in 2025, but positive cash flow from operations of $1.27 billion provides liquidity. A new fragrance launch and executive appointment signal ongoing brand development efforts.
The stock presents a mixed outlook. Analyst sentiment is divided with a slight Hold bias, yet technical momentum and earnings beats offer near-term upside potential. Key risks include sustained negative net income margins, high debt levels, and competitive pressures in the beauty sector. The upcoming Q2 2026 earnings report on August 19, 2026, will be critical for validating the recent positive earnings trend and guiding future price direction.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
